Send to printer »

Insight & Intelligence™ : Sep 18, 2012

GEN Ten: Young Guns of Biopharma

Which biopharm execs haven't reached middle age yet? Find out here.

George Bernard Shaw once commented that “Youth is wasted on the young.” But the GEN TEN list of under-40 biopharma hotshots indicates, instead, that youth is being served. From positions as president and CEO to division head and co-founder, young professionals under 40 are already making an impact on the global bioindustry. And they will certainly play key roles in shaping its future.

Below is a list of biopharma executives under 40 years old, as verified by their employers or as reported in local or trade publications that have included them in their own “Under 40” lists within the past year.

Vance Vanier, M.D.

CEO, Navigenics (acquired by Life Technologies in July)

38 years old1

Chad Robins

CEO & President, Adaptive Biotechnologies

38 years old

Brian McVeigh

VP, Worldwide Business Development, Transactions & Investment Management, GlaxoSmithKline

39 years old2

Andrew Asa Hindman

President & CEO, Tobira Therapeutics

39 years old

Al Hawkins

CEO, Milo Biotechnology and VP of Business Development, BioMotiv

37 years old

Uday Gupta

CEO, Global Cell Solutions and ProteiosBio

38 years old on June 13

Jeff George

Division Head, Sandoz, Novartis

39 years old

Van Bui

Treasurer, Genentech

38 years old4

Steven Axon

VP of Business Development, North America; Head of Global Business Development, Fertility, and Endocrinology, EMD Serono

37 years old

Adeyemi (Yemi) Adesokan, Ph.D.

Co-Founder & CEO, Pathogenica

35 years old